Franz Obermayr

Franz Obermayr previously served as CEO of Eyegate (now Kiora NASDAQ: KPRX), before that he was founder and CEO of Panoptes which was sold to Eyegate in 2020. Before founding Panoptes he served as head of clinical development at Nabriva (NASDAQ: NBRV) leading to approval of Xenleta in 2019. Franz has been in different roles throughout his career in drug development covering areas in infectious, inflammatory and oncology indications and did his PhD in Biochemistry at the Imperial Cancer Research Fund.